Severe Malaria, Pascalian Therapeutics, and the US Food and Drug Administration (FDA)
- PMID: 35023549
- DOI: 10.1093/cid/ciac024
Severe Malaria, Pascalian Therapeutics, and the US Food and Drug Administration (FDA)
Conflict of interest statement
Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment in
-
Optimizing Antimicrobial and Host-Directed Therapies to Improve Clinical Outcomes of Childhood Tuberculous Meningitis.Clin Infect Dis. 2022 Aug 25;75(2):360-361. doi: 10.1093/cid/ciab1036. Clin Infect Dis. 2022. PMID: 34910810 Free PMC article. No abstract available.
-
Reply to White et al.Clin Infect Dis. 2022 Aug 25;75(2):359. doi: 10.1093/cid/ciac025. Clin Infect Dis. 2022. PMID: 35023546 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
